{"contentid": 488563, "importid": NaN, "name": "Coronavirus cocktail boosts Regeneron in first quarter", "introduction": "An estimate-beating first quarter performance lifted shares in New York\u00e2\u0080\u0099s Regeneron Pharmaceuticals over 3% on Thursday, with revenues up 38% at $2.5 billion.", "content": "<p>An estimate-beating first quarter performance lifted shares in New York&rsquo;s Regeneron Pharmaceuticals (Nasdaq: REGN) over 3% on Thursday, with revenues up 38% at $2.5 billion.</p>\n<p>Net income came in at $1.1 billion, an increase of 78% on the same period of 2020, a little over $10 per share following Generally Accepted Accounting Principles (GAAP).</p>\n<p>Chief executive Leonard Schleifer said the result reflected the firm&rsquo;s evolution into &ldquo;a company with multiple durable product lines helping people with a range of serious diseases including COVID-19.&rdquo;</p>\n<p>Looking to diversify around cornerstone product Eylea (aflibercept), Dr Schleifer noted progress in oncology, where the firm is launching Libtayo (cemiplimab-rwlc) in advanced basal cell carcinoma and non-small cell lung cancer (NSCLC).</p>\n<p>Regeneron also recently announced positive pivotal data for the therapy in cervical cancer, and is planning regulatory submissions later in the year.</p>\n<h2>Revenue drivers</h2>\n<p>Several large cap biotechs have reported a disappointing start to the year, with notable exceptions including coronavirus vaccine developers Pfizer (NYSE: PFE) and Johnson &amp; Johnson (NYSE: JNJ).</p>\n<p>Regenereon too has played a role in combating the novel coronavirus, with antibody cocktail REGEN-COV (casirivimab/imdevimab) securing emergency approval to treat the disease in the USA.</p>\n<p>The therapy, which has continued to demonstrate efficacy against coronavirus variants, took in $262 million in first-quarter sales.</p>\n<p>The company also recently reported positive Phase III results for REGEN-COV in both the COVID-19 outpatient treatment and prevention settings, and is working with regulatory authorities to bolster access.</p>\n<p>While the firm is working on broadening its pipeline, performance continues to be driven primarily by eye drug Eylea, revenues from which grew to $1.3 billion, up from $1.2 billion.</p>\n<p>Dr Schleifer said: &ldquo;We expect continued growth with Eylea in retinal diseases, as well as with Dupixent through further penetration in existing indications and a broad Phase III development program.&rdquo;</p>\n<p>Sanofi-partnered (Euronext: SAN) Dupixent (dupilumab) sold well, with Regeneron&rsquo;s overall profit share from commercialization of antibodies rising to $261 million, compared to $171 million in the first quarter of 2020.</p>\n<h2>Selected product performance</h2>\n<p>Eylea - $1.34 billion, up 14.5% from $1.17 billion.</p>\n<p>Libtayo - $69 million, up 11.3% from $62 million.</p>\n<p>REGEN-COV - $262 million.</p>\n<p>&nbsp;</p>\n<p>&nbsp;</p>", "date": "2021-05-07 11:16:00", "meta_title": NaN, "meta_keywords": "billion, Regeneron, quarter, coronavirus, performance, million, revenues, cocktail, antibody, Eylea, lifts, Pharmaceuticals, Thursday, shares, lifted, cell", "meta_description": "An estimate-beating first quarter performance lifted shares in New York\u00e2\u0080\u0099s Regeneron Pharmaceuticals over 3% on Thursday, with revenues up 38% at $2.5 billion.", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-07 10:22:14", "updated": "2021-05-07 11:16:25", "access": NaN, "url": "https://www.thepharmaletter.com/article/coronavirus-antibody-cocktail-lifts-regeneron-in-first-quarter", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "regeneron_big.jpg", "image2id": "regeneron_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Anti-virals, Immunologicals, Infectious diseases, Oncology, Ophthalmics", "topic_tag": "Coronavirus, Drug Trial, Financial, Focus On, Management, Research", "geography_tag": "USA", "company_tag": "Regeneron Pharmaceuticals", "drug_tag": "Dupixent, Eylea, Libtayo, REGN-COV2", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-07 11:16:00"}